Mylan launches generic version of Abbott's Teveten

Drug maker to receive 180 days of market exclusivity

PITTSBURGH — Mylan has launched a generic drug for treating high blood pressure, the company said.

The drug maker announced the launch of eprosartan mesylate tablets in the 400-mg and 600-mg strengths. The drug is a generic version of Abbott's Teveten and is used to treat hypertension.

Mylan was the first company to file a regulatory approval application with the Food and Drug Administration for the drug, thus entitling it to 180 days of market exclusivity in which to compete directly with Abbott. After that period, any company that wins approval from the FDA will be able to market a generic version of Teveten.

Teveten had sales of $4.9 million during the 12-month period ended in September, according to IMS Health.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Recommended stories

Login or Register to post a comment.